China’s vaccine landscape is shifting after local biotech Xiamen Innovax Biotech unveiled the country’s first domestically ...

Merck & Co., Inc. is acquiring Verona Pharma plc for $10bn to bolster long-term growth with COPD drug Ohtuvayre. Click for my ...

Multinational pharmaceutical companies (MNCs) are facing significant challenges in China's vaccine market, as regulatory ...

Vaccine businesses seen as valuable parts of pharma groups but government hostility could deter future developments ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

Merck MRK announced a definitive agreement to acquire Verona Pharma VRNA for approximately $10 billion. The deal will add ...

China’s first domestically made nine-valent HPV vaccine, a direct competitor to Merck’s Gardasil 9, is being priced at 499 ...

Merck & Co., Inc. (NYSE:MRK) is one of the 10 best defensive stocks to buy in a volatile market. On July 2, UBS reiterated a ...

Merck (MRK) stock gains as CDC's draft agenda for an upcoming meeting excludes HPV vaccine dose changes, favoring the company's Gardasil vaccine. Read more here.

Merck's HPV vaccine Gardasil 9. Courtesy photo Plaintiffs’ attorneys have asked a federal appeals court to reinstate more than 100 lawsuits tying the HPV vaccine Gardasil to autoimmune diseases.

The HPV vaccine is one of the most powerful vaccines ever developed: It is unusual among immunizations in that it durably prevents infection and disease at rates close to 100 percent.

A CDC advisory panel on Thursday voted 5-2 to recommend the use of a new preventative RSV therapy in babies, Merck’s Enflonsia.